Neuren Pharmaceuticals Limited is a biopharmaceutical company with a unique product pipeline applicable to two of the world's largest and fastest growing therapeutic markets: neuroprotection and metabolism. The pipeline comprises compounds which mimic innate CNS protection and repair mechanisms and those which regulate growth and metabolism. Key indications include acute and chronic neurodegenerative conditions such as stroke, head injury, Parkinson's disease, cognitive impairment, multiple sclerosis as well as disorders of growth and metabolism. The Company has five families of compounds in various stages of development for neurological and metabolic disorders. This portfolio is based on an exceptionally strong patent estate and backed by world class drug discovery and development expertise.
The Company's key attributes include:
Unique Scientific Rationale - based on molecules that occur naturally in the body and on well characterised biological systems and pathways.
Large, Patented Pipeline - five families of compounds covered by 72 individual patents and/or patent applications in Australia, New Zealand, Japan, Europe and the U.S.
Credible Partners and Collaborators - including Pfizer also a shareholder, Duke University (Durham, North Carolina, USA), Walter Reed Army Institute of Research (Silver Spring, Maryland, USA), University of Texas Medical School (Houston, Texas, USA), and Metabolic Pharmaceuticals Limited (Melbourne, Australia).
Large Market Opportunity - targeted markets have significant unmet need with little or no current competition. In the initial targeted areas of neuroprotection for Cardiac Surgery, Stroke and Traumatic Brain Injury and later the chronic diseases (such as Multiple Sclerosis, Parkinson's Disease and Alzheimer's Disease), the estimated market opportunity in major markets is over US$11.0 billion per annum. The therapeutic targets in diseases of growth and metabolism (such as Metabolic Syndrome and Breast Cancer) have estimated markets of over US$7.0 billion per annum.
Effective and Efficient Clinical Development Strategy - conducting trials in conditions that provide readily available patients, maximum control, minimum timeframes and outcomes that are indicative of efficacy in additional and larger indications.
Successful Phase I Trials - the first lead candidate Glypromate® has successfully completed Phase I trials. Glypromate® will commence Phase II trials in 2005, aimed at alleviating the cognitive deficit resulting from cardiac bypass surgery. Further, Neuren's aims is to move its other lead candidates into clinical trials, with the second lead candidate progressing into a Phase I trial planned for 2005 and additional Phase II trials planned for 2006 and 2007.
Sound Commercialisation Strategy - developing early collaborations and partnerships with groups able to validate products, reduce risks, enhance skills and provide contract revenue. The key strategy for revenue generation is outlicencing of drug candidates post Phase II clinical trials.
Experienced Management and Board - with skills covering biopharmaceutical product development from basic research and discovery, through preclinical and clinical development, to market approval and commercialisation. Neuren scientists and consultants have published more than 400 scientific papers.
updated 22nd March, 2006
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |